CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:	GALLAGHER Peter Thaddeus	Group Art Unit: -1626
Serial No.:	10/575469	Examiner: - Anderson, Rebecca L
Application Date:	December 10, 2004	Conf No.: 3213
US Nat'l Entry Date (if applicable):	April 12, 2006	
For:	MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS	
Docket No.:	X16177	

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Examiner:

Introductory Comments

The following is a response to the Office Action dated March 2.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 5 of this paper.

Amendments to the Specification

Please replace the paragraph on page 55, line 10 with the following: 2-[l-Phenvl-2-(2-~~trifluoromethanesulfonyloxy~~hydroxy-phenyl)-ethyl]-morpholine-4-carboxylic acid tert-butyl ester.

Please replace the paragraph beginning on page 56, line 2 with the following: Add NaH 95% (17 mg, 0.68 mmol), at 0°C, to a solution of 2-[l-Phenvl-2-(2-~~trifluoromethanesulfonyloxy~~hydroxy-phenyl)-ethyl]-morpholine-4-carboxylic acid tert-butyl ester(218 mg, 0.568 mmnol) in 2 ml of dry DMF and stir for 15 min; then add N-phenyl-bis(trifluoromethanesulfonimide) (224 mg, 0.625 mmol) and stir the reaction at room temperature for 2 h. Add aqueous saturated solution of Na_2CO_3 and Et_2O, separate the organic phase, wash with H_2O, dry over Na_2SO_4, filter and remove the solvent to give a residue. Purify the residue by column chromatography on silica gel eluting with CH_2Cl_2:AcOEt 98:2 to afford the title compound.

Please replace the paragraph beginning on page 58, line 12, with the following: Example 11: 4-Benzyl-2-(1,2-Diphenyl-ethyl)-morpholine (mixture of stereoisomers).